TO BE PRINTED ON LOCAL TRUST HEADED PAPER

<Doctor>

<Practice>

<Street>

<City>

<Postcode>

<Date>

Dear Dr *<GP name>,*

**Notification of patient recruitment to STOPping Anticoagulation for isolated or incidental subsegmental Pulmonary Embolism (STOP-APE).**

# Re: Name:……………………………………………………………………………………………………….

# DOB: ………………………………………………………………………………………………………..

**NHS No:…………………………………………………………………………………………………….**

I am writing to inform you that your patient named above has consented to take part in the **STOP-APE** trial**.** This investigator led multi-centre, prospective, open-label, randomised controlled clinical trial will test the hypothesis: if withholding anticoagulation is non-inferior to standard anticoagulation therapy in the treatment of isolated or incidental subsegmental pulmonary embolism (SSPE) for preventing symptomatic recurrent venous thromboembolism or superior for clinically relevant bleeding over 3 months.

The trial will recruit 1466 people aged 18 and over with SSPE confirmed by computed tomography pulmonary angiogram (CTPA).

**This patient has been randomised to the following arm:**

**Control arm – standard anti-coagulation therapy**

Under the control arm, the patient should continue on ‘standard care’ and continue with their anti-coagulation therapy. The normal contraindications and safety precautions for use of these treatments should be adhered to, as per routine care.

**Intervention arm – withholding anti-coagulation therapy**

Under the intervention arm, the patient has had anti-coagulation treatment withheld. Any anticoagulation treatment that the patient had been previously provided will be discontinued.

The patient will be followed up by the research team at *<enter name of site>.* STOP-APE is being coordinated by the University of Birmingham Clinical Trials Unit (address below), and is being funded by the Health Technology Assessment Programme which is part of the National Institute for Health Research (NIHR), Ref. No **NIHR128073**. The trial has been approved by Wales REC 6. STOP-APE is sponsored by University of Birmingham. The Chief Investigator is Prof Daniel Lasserson Professor of Acute Ambulatory Care.

If you have cause to see your patient during the course of the trial and want to discuss any aspect of their management e.g. treatment regimen, contra-indications etc., please do not hesitate to contact me on Tel: *<insert responsible clinician telephone number>*.

If you have any questions or would like any more information please contact *<insert responsible clinician name>* on *<insert responsible clinician telephone number>*.

Yours sincerely,

*<insert responsible clinician name>*

STOP-APE Trial Office, The University of Birmingham Clinical Trials Unit, Institute of Applied Health Research, Public Health Building, University of Birmingham, Edgbaston, Birmingham, B15 2TT.

Web address: [www.birmingham.ac.uk/stop-ape](http://www.birmingham.ac.uk/stop-ape)

Email address: [stopape@trials.bham.ac.uk](mailto:stopape@trials.bham.ac.uk)